India needs to invest more in research to create better ecosystem: Biocon Chief Kiran Mazumdar-Shaw
New Delhi: India needs to incentivize industries to invest more in academic research for creating a better ecosystem of research and innovation, Biocon chairperson Kiran Mazumdar-Shaw said on Wednesday.Kiran Mazumdar-Shaw is a first-generation entrepreneur and global business leader with over 4 decades of experience in biotechnology which she started in 1978 from her garage in India.Speaking at...
New Delhi: India needs to incentivize industries to invest more in academic research for creating a better ecosystem of research and innovation, Biocon chairperson Kiran Mazumdar-Shaw said on Wednesday.
Kiran Mazumdar-Shaw is a first-generation entrepreneur and global business leader with over 4 decades of experience in biotechnology which she started in 1978 from her garage in India.
Speaking at a book launch event organised by the Centre for Social and Economic Progress (CSEP), Mazumdar-Shaw further said as the government has come up with incentives for production, it should also come up with incentives for research.
"India needs to incentivize industries to invest more in academic research to create a better ecosystem of research and innovation".
Read also: Biocon arm gets DCGI nod to initiate clinical study for Itolizumab
Speaking at the event, former Niti Aayog Vice-Chairman Arvind Panagariya said due to economic reforms India's growth accelerated from 3 per cent (before liberalisation) to 7-8 per cent.
Former deputy chairman of erstwhile Planning Commission Montek Singh Ahluwalia said the difference between 1991 and now is that in 1991, there was a global consensus on what to do.
Read also: Biocon arm bags USFDA approval for Posaconazole Delayed-Release tablets
"We (India) were the only odd guys out. But today, that consensus has more or less disappeared," Ahluwalia said.
"He said there is this view that digitalisation is creating so much power on the part of the big guys to mine data, that the whole idea that markets lead to rational allocations in the light of consumer decision-making is totally undermined," reports PTI.
Read also:Biocon listed on Dow Jones Sustainability Emerging Markets Index
Biocon Biologics has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases.
Five molecules from Biocon Biologics' portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd